Project Description

Considering there is no effective treatment for osteoarthritis, my main goal is to develop a drug screening path that allows the assessment of new molecules as possible therapy for osteoarthritis. To identify and validate drug targets, focus will be set on the modulation of inflammation induced hypertrophy and endochondral ossification.  In order to achieve this, Lilly will provide a library of compounds of which the effect will be evaluated in culture models for hypertrophic chondrocytes and articular cartilage in vitro. Further evaluation of promising candidates will be made in vivo to prevent osteoarthritis development in a mouse model of posttraumatic osteoarthritis.